As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
Eylea 2mg (intravitreal aflibercept injection) is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina
The move represents a significant milestone in Lupin’s strategy to expand its specialty care portfolio and strengthen its presence in Europe
The center brings together hands on technology demonstrations, application expertise, and commercial operations
The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country
The impact on Phase III trials is particularly significant, as these later-stage studies involve larger, committed patient populations and represent years of investment
The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
The company now offers the complete range of Apomorphine Hydrochloride in different fill volumes
Broadens downstream purification portfolio with next-generation Protein A chromatography for scalable manufacturing
The investigational new drug application with FDA was actually for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate aimed at solid tumors
Subscribe To Our Newsletter & Stay Updated
